interferon alfa-2b
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Viraferon | — | 2008-10-13 | europa.eu ↗ |
| Label expansions (7) | US (FDA) | INTRON A | — | 1992-07-13 – 2001-06-21 | fda.gov ↗ |
| Approved | EU (EMA) | IntronA | — | 2000-03-09 | europa.eu ↗ |
| Approved | US (FDA) | INTRON A | — | 1986-06-04 | fda.gov ↗ |
Trials 177 · started per year
Also used as a comparator or background therapy in 44 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07199413 Background | Jun 2026 → Apr 2029 | malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT01603212 Background | Jul 2013 → Jul 2017 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01608594 Background | May 2013 → Feb 2017 | melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase 1 | NCT01409174 Background | Feb 2013 → May 2016 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00311558 Background | Oct 2005 → May 2011 | cancer | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT00016042 Background | Jan 2001 → ? | colorectal cancer, kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03066947 Background | May 2017 → Nov 2018 | breast cancer | BriaCell Therapeutics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01483248 Comparator | Oct 2010 → Oct 2013 | cirrhosis of liver | S-Evans Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01121731 Comparator | May 2010 → Oct 2012 | chronic hepatitis C virus infection | Digna Biotech S.L. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT02737046 Background | Dec 2016 → Dec 2024 | adult T-cell leukemia/lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT01274273 Comparator | Oct 2009 → Dec 2015 | renal cell carcinoma | University of Aarhus | Unknown | No outcome recorded |
| Phase 2 | NCT00613509 Comparator | Jun 2008 → Apr 2010 | cancer, melanoma | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT00485563 Background | Jun 2007 → Aug 2008 | renal cell carcinoma | Endocyte | Terminated | No outcome recorded |
| Phase 2 | NCT00763763 Background | Dec 2004 → Oct 2007 | Philadelphia-positive myelogenous leukemia, acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00092222 Comparator | Oct 2004 → Oct 2026 expected | HIV infectious disease, cancer, human herpesvirus 8 infection, lymphoproliferative syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00250796 Comparator | Sep 2000 → Jan 2006 | cancer, liver disorder | University of New Mexico | Completed | No outcome recorded |
| Phase 2 | NCT00005986 Background | Aug 2000 → Sep 2004 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00002773 Background | May 1996 → Apr 2004 | pancreatic adenocarcinoma | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00002475 Background | Apr 1991 → Dec 2007 | breast cancer, colorectal cancer, kidney cancer, lung cancer +2 | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT01729663 Comparator | Apr 2009 → Dec 2018 | cutaneous melanoma | Laboratorio Pablo Cassará S.R.L. | Unknown | No outcome recorded |
| Phase 2/3 | NCT00275938 Background | Oct 1998 → Jun 2001 | chronic hepatitis B virus infection | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03537274 Comparator | Aug 1997 → Jul 1999 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT00538811 Background | — | hepatitis C virus infection | Aga Khan University | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT04116502 Comparator | Oct 2019 → Oct 2028 expected | acquired polycythemia vera | University of Birmingham | Recruiting | No outcome recorded |
| Phase 3 | NCT01860742 Comparator | Dec 2014 → Oct 2016 | digestive system neuroendocrine neoplasm | Jules Bordet Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT03435302 Comparator | Feb 2014 → Feb 2018 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 3 | NCT01681446 Comparator | Aug 2012 → Aug 2019 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00647465 Comparator | Oct 2005 → May 2006 | influenza | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00311467 Comparator | Mar 2004 → May 2007 | renal cell carcinoma | Central European Cooperative Oncology Group | Terminated | No outcome recorded |
| Phase 3 | NCT00209209 Comparator | Jan 2004 → Dec 2018 | mantle cell lymphoma | European Mantle Cell Lymphoma Network | Unknown | No outcome recorded |
| Phase 3 | NCT00633542 Comparator | Jun 2003 → Sep 2007 | plasma cell myeloma | Marche Polytechnic University | Completed | No outcome recorded |
| Phase 3 | NCT00221702 Comparator | Jun 2003 → Oct 2010 | cutaneous melanoma, metastatic neoplasm | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00005966 Background | Oct 2000 → Mar 2006 | renal cell carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00083551 Comparator | Aug 1998 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT00577993 Comparator | Mar 1998 → Aug 2017 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002835 Background | Oct 1995 → Feb 2004 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002599 Background | Sep 1994 → ? | plasma cell myeloma | Medical Research Council | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02323659 Comparator | Jun 2014 → Mar 2018 | mycosis fungoides | Polish Lymphoma Research Group | Terminated | No outcome recorded |
| Phase 4 | NCT02199327 Comparator | May 2014 → Dec 2016 | conjunctival intraepithelial neoplasm, corneal intraepithelial neoplasm | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00375661 Comparator | Sep 2006 → Mar 2012 | chronic hepatitis C virus infection | Kyoto University | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04295551 Background | Mar → Jul 2020 | COVID-19 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
| — | NCT00838968 Comparator | Jan 2008 → Oct 2012 | hepatocellular carcinoma | Fudan University | Withdrawn | No outcome recorded |
| — | NCT02454764 Comparator | ? → Jan 2018 | hepatitis B virus infection | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
Evidence & citations 45 cited values
Every value below carries the sentence it was read from. 235 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon alfa-2b | “The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with the drugs Intron-A...” NCT01409187 ↗65“OBJECTIVES: I. Evaluate the toxic effects, patient tolerance, and practicality of administering interferon alfa-2b, fluorouracil, interleukin-2, and isotretinoin (FUNIL-cRa) in...” NCT00003585 ↗ “The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is...” NCT01192698 ↗ “If a complete response was not seen after 8 weeks, interferon alfa-2b 3 million units (MU) subcutaneously was added, and increased to 5 MU if tolerated, 3 times a week.” PMID 17366595 ↗ May 2007 “patients with low-grade disease received dose-escalated interferon alfa-2b, starting at 7·5 million international units subcutaneously three times per week” PMID 37011643 ↗ Mar 2023 “Patients receive tretinoin liposome IV over 30 minutes once weekly and interferon alfa-2b subcutaneously on five consecutive days (M-F) for 8 weeks.” NCT00003656 ↗ “Interferon alfa-2b (IFN-A) maintenance is administered 3 times per week following bone marrow recovery from the first or second L-PAM courses.” NCT00003007 ↗ “Patients assigned to arms II or III also receive interferon alfa-2b subcutaneously, at one of two doses, three times a week for 2 years.” NCT00004104 ↗ “Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma” NCT00026143 ↗ “Patients receive fluorouracil IV over 24 hours on day 6 of week 2 and interferon alfa-2b SC and GM-CSF SC 3 times weekly on weeks 3-5.” NCT00030342 ↗ “Patients receive subcutaneous interferon alfa-2b every other day three times per week for 12 months.” NCT00004040 ↗ “Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma” PMID 26503196 ↗ Oct 2015 “Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗ “Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗ “Interferon alfa-2b is a drug that activates an immune response to infections in the body.” NCT00629200 ↗ “Patients receive interferon alfa-2b subcutaneously (SC) twice daily beginning on day 1.” NCT00005966 ↗ “Patients receive MEP vaccine as in arm I and interferon alfa-2b SC three times a week.” NCT00006385 ↗ “Patients will be randomly assigned to receive Methotrexate or Interferon Alfa 2b.” NCT02323659 ↗ “allogeneic melanoma vaccine plus interferon alfa-2b (IFN-A) vs. IFN-A alone” NCT00002767 ↗ “Interferon alfa-2b may interfere with the growth of the cancer cells.” NCT00006384 ↗ “Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse.” NCT00560053 ↗ “interferon alfa-2b may interfere with the growth of cancer cells.” NCT00003444 ↗ “High-dose Interferon Alfa-2b and Anti-CTLA4 Monoclonal Antibody” NCT00610857 ↗ “interferon alfa 2b (IFN-A2b) subcutaneously three times a week” NCT00003263 ↗ “Interferon Alfa-2b will be given concurrently with ipilimumab.” NCT01608594 ↗ “interferon alfa-2b as postsurgical adjuvant therapy” NCT00003715 ↗ “adjuvant interferon alfa-2b (IFNα-2b) therapy” PMID 22104564 ↗ Jan 2012 “high-dose subcutaneous interferon alfa-2b” NCT00003091 ↗ “5-Fluorouracil Interferon-alfa-2b” NCT01658813 ↗ “Interferon Alfa-2b AND RIBAVIRIN” NCT01463592 ↗ “Drug: Interferon Alfa-2b” NCT01462773 ↗ |
| Known as | aIFN | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗ |
| Known as | Alfainterferona 2b Humana Recombinante | “Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da...” NCT01841775 ↗ |
| Known as | alpha-interferon | “followed by maintenance with alpha-interferon (arm A) or thalidomide 50 mg daily (arm B).” PMID 19880501 ↗ Oct 20096“Alpha-interferon will be given once a day for an initial period of 12 weeks.” NCT00038376 ↗ “Alpha-interferon nebulization” NCT04295551 ↗ |
| Known as | Bifendatatum | “Bifendatatum” NCT01483248 ↗ |
| Known as | Bioferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634094 ↗ |
| Known as | HDI | “We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic complete responses (pCR).” PMID 30352626 ↗ Oct 20181“Pembrolizumab and high dose interferon alfa-2b (HDI)” NCT02339324 ↗ |
| Known as | hrIFN-a | “We hypothesize that ingested human recombinant interferon-alpha (hrIFN-a) will prolong the "honeymoon" period and enhance B cell survival in type 1 diabetes in a phase II...” NCT00005665 ↗ |
| Known as | Human interferon a2b injection | “Generic name: Human interferon a2b injection; Dosage form: solution; Dosage: 1ml: 3 million IU;” NCT05912946 ↗ |
| Known as | Human Serum Albumin/interferon alpha2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781753 ↗ |
| Known as | IFN | “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗2“outpatient subcutaneous (s.c.) interferon-alpha2b (IFN), followed by an inpatient hybrid schedule” PMID 16706633 ↗ Apr 2006 “Interferon -IFN (3 MU/sm x 3 times/week, x 12 weeks)” NCT00842114 ↗ |
| Known as | IFN alfa-2b | “To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C.” NCT00001035 ↗1“Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b” NCT02339324 ↗ |
| Known as | IFN-A | “Interferon alfa-2b (IFN-A) maintenance is administered 3 times per week following bone marrow recovery from the first or second L-PAM courses.” NCT00003007 ↗9“Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗ “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ “allogeneic melanoma vaccine plus interferon alfa-2b (IFN-A) vs. IFN-A alone” NCT00002767 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously 3 times a week.” NCT00045370 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously (SQ) daily.” NCT00006343 ↗ “interferon alfa (IFN-A) subcutaneously once daily or 3 times weekly” NCT00015847 ↗ “interferon-alpha (IFN-a) subcutaneous (SC) injections” NCT00333840 ↗ “Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ “interferon alfa (IFN-A)” NCT00002733 ↗ |
| Known as | IFN-A2b | “sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF ), interferon alfa-2b ( IFN-A2b ), and zidovudine ( AZT )” NCT00000694 ↗4“three subcutaneous injections of IFNa-2b (6 MiU, Schering -Plough Corp.)” NCT00913913 ↗ “interferon alfa 2b (IFN-A2b) subcutaneously three times a week” NCT00003263 ↗ “Recombinant Alpha Interferon (IFN-A2b)” NCT00002270 ↗ |
| Known as | IFN-alpha | “In combination with IFN-alpha in selected, good prognosis metastatic renal cell carcinoma patients, i.v. IL-2 offers no significant advantage over s.c. IL-2 and induces higher toxicity.” PMID 18794104 ↗ Sep 20082“interferon alpha-2b (IFN-alpha) and ribavirin plus either” PMID 22755276 ↗ Apr 2012 “interferon-alpha (IFN-alpha)” NCT01681446 ↗ |
| Known as | IFN-alpha 2B | “IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week” PMID 19228745 ↗ Feb 2009 |
| Known as | IFN-α | “postresection intravesical BCG (81 mg [n=50] or 27 mg [n=19]) or BCG (27 mg) with interferon alpha (IFN-α; n=30).” PMID 21163569 ↗ Dec 20103“Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily” NCT02331706 ↗ “interferon alfa (IFN-α) subcutaneously (SC) three times weekly” NCT00416871 ↗ “Interferon (IFNα, Roferon-A)” NCT00962715 ↗ |
| Known as | IFNα-2b | “Patients with stage III resected lymph node or in-transit metastasis from cutaneous malignant melanoma were randomly assigned to receive either a standard HDI regimen or three...” PMID 26503196 ↗ Oct 20159“Subcutaneous injections of recombinant human IFN-α-2b were performed for 6 cycles, and prolonged IFN-α therapy could be permitted at the request of patients.” PMID 35154096 ↗ Jan 2022 “Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.” PMID 30352626 ↗ Oct 2018 “Subcutaneous injections of recombinant human IFN-α-2b were performed for 6 cycles, and prolonged IFN-α therapy could be permitted at the request of patients.” PMID 35154096 ↗ Jan 2022 “IFN-α-2b was administered at 3 million units three times a week subcutaneously for 24 weeks” PMID 31371315 ↗ Aug 2019 “adjuvant interferon alfa-2b (IFNα-2b) therapy” PMID 22104564 ↗ Jan 2012 “Interferon-α-2b (IFNα-2b)” NCT00913913 ↗ “IFN α2b” NCT05381363 ↗ |
| Known as | INF alpha | “the cytokines Interleukin-2 (IL-2) and Interferon-alpha (INF-alpha)” NCT00485563 ↗1“Recombinant Interferon Alfa (INF alpha)” NCT00002965 ↗ |
| Known as | INF-a | “interferon-alpha (INF-a)” NCT00333840 ↗ |
| Known as | INFα 2b | “Among the drugs used the investigators have mitomycin C (MMC) and interferon alpha 2b (INFα 2b).” NCT02199327 ↗ |
| Known as | Interferon | “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗12“Interferon -IFN (3 MU/sm x 3 times/week, x 12 weeks)” NCT00842114 ↗ |
| Known as | interferon alfa | “Patients receive chemo/immunotherapy comprising fluorouracil IV continuously over 24 hours on day 13 and GM-CSF and interferon alfa SC on days 17, 19, 21, 24, 26, and 28.” NCT00016042 ↗8“Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma” PMID 20153039 ↗ Feb 2010 “Patients receive maintenance therapy with interferon alfa SC 3 times weekly until progression or after 3 months if no partial response.” NCT00028886 ↗ “receive subcutaneous interferon alfa injections 3 times a week for 5 years or until disease progression, relapse, or toxicity.” NCT00003416 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously (SQ) daily.” NCT00006343 ↗ “interferon alfa (IFN-A) subcutaneously once daily or 3 times weekly” NCT00015847 ↗ “interferon alfa (IFN-α) subcutaneously (SC) three times weekly” NCT00416871 ↗ “Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ “interferon alfa (IFN-A)” NCT00002733 ↗ |
| Known as | interferon alfa-2a | “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma” PMID 20153039 ↗ Feb 2010 |
| Known as | Interferon Alpha | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗34“Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma” NCT00053820 ↗ “Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.” NCT00311467 ↗ “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ “Maintenance with interferon alpha will be administered until disease progression.” NCT00580372 ↗ “using interferon-alpha (Roferon) and Isotretinoin (Accutane).” NCT00038376 ↗ “standard regimen of interferon-alpha plus cytarabine” PMID 19648168 ↗ Jul 2009 |
| Known as | Interferon Alpha-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05756166 ↗ |
| Known as | interferon-alpha-2b | “The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood” NCT00226408 ↗28“We conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-α-2b)” PMID 31371315 ↗ Aug 2019 “Among the drugs used the investigators have mitomycin C (MMC) and interferon alpha 2b (INFα 2b).” NCT02199327 ↗ “INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg” NCT01463592 ↗ “Interferon alpha-2b 5 million units per nebulizer BID.” NCT04349410 ↗ |
| Known as | Interferon-α-2b | “standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗9“Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy.” NCT01276730 ↗ “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ “Interferon α2b gel treatment for 30 days.” NCT06137950 ↗ “Interferon-α-2b (IFNα-2b)” NCT00913913 ↗ |
| Known as | Interferon-α2b (IFN) | “Interferon-α2b (IFN)” NCT02615574 ↗ |
| Known as | Intron A | “The study was originally designed for lymphoblastoid α-interferon; then soon after trial approval by the NCI-Milan Scientific and Ethic Committee (#98-016) the protocol was...” NCT00273247 ↗13“1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.” NCT00686478 ↗ “IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week” PMID 19228745 ↗ Feb 2009 “interferon alfa-2b (Intron-A, Schering-Plough, Kenilworth, NJ)” PMID 17366595 ↗ May 2007 “SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.” NCT00908869 ↗ “I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC.” NCT01462773 ↗ “IntronA 3miu TIWW SC for 18 months” NCT00221702 ↗ “low dose IFN-alpha 2B (Intron-A)” PMID 14581348 ↗ Oct 2003 “Interferon Alpha-2b (Intron A)” NCT00293527 ↗ “Intron A, Interferon alpha -2b” NCT00613509 ↗ “Interferon α-2b (INTRON® A)” NCT01121731 ↗ “Drug: intron A” NCT00221702 ↗ |
| Known as | Intron-A: IFN-α2b | “Intron-A®: IFN-α2b” NCT00613509 ↗ |
| Known as | Locteron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00863239 ↗ |
| Known as | NSC-367982 | “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ |
| Known as | NSC-377523 | “Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗2“with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ “Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ |
| Known as | PEG-Intron | “The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease...” NCT00522249 ↗2“Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum...” NCT01639885 ↗ “immune enhancer interferon-α (Peg-Intron)” PMID 26216383 ↗ Jul 2015 |
| Known as | Pegylated Alfa Interferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00522249 ↗ |
| Known as | recombinant human interferon α-2b | “recombinant human interferon α-2b” NCT07635459 ↗ |
| Known as | Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein | “characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in healthy subjects.” NCT02781753 ↗ |
| Known as | recombinant interferon alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005986 ↗65 |
| Known as | Recombinant Interferon Alfa-2b | “Biological: Recombinant Interferon Alfa-2b” NCT00126594 ↗ |
| Known as | Roferon | “using interferon-alpha (Roferon) and Isotretinoin (Accutane).” NCT00038376 ↗ |
| Known as | Veldona | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00483184 ↗ |
| Action | Inhibit | “IFN alfa-2b has HIV inhibitory properties” NCT00001035 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Alpha Interferon” NCT00000694 ↗ |
| Route | Subcutaneous | “IFN-A2b and GM-CSF are given in two separate injections under the skin (subcutaneous injection) once a day” NCT00000694 ↗ |